Aflibercept, bevacizumab, and ranibizumab all improve vision in eyes with center-involved diabetic macular edema, according to a randomized clinical trial. The relative effect of the three drugs ...

The Diabetic Retinopathy Clinical Research Network (DRCR.net) conducted a comparative effectiveness trial evaluating the prevalence of persistent diabetic macular edema (DME) and its effect on visual ...

Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ® ...

Patricia DeLucia has spent decades studying something many of us never think about: judgments about collisions that are crucial for safety. But the roots of her research stretch back to her childhood, ...

Please provide your email address to receive an email when new articles are posted on . At 2 years, 74% of Black patients and 66.4% of white patients who received ranibizumab achieved vision of 20/40 ...

Visual acuity outcomes are comparable in diabetic macular oedema patients who receive laser treatment 24 weeks or more after initiation of ranibizumab injections and those for whom laser therapy is ...